Edwards Lifesciences Corporation (NYSE:EW) should head towards $117.14 per share according to 14 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $100 per share. The higher price estimate target is at $132 according to the Analysts.
Many analysts have stated their opinion on the company shares. Guggenheim Securities initiates coverage on Edwards Lifesciences Corporation (NYSE:EW). The current rating of the shares is Neutral, according to the research report released by the firm. The rating by the firm was issued on June 9, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, The director officer (Chairman & CEO), of Edwards Lifesciences Corp, Mussallem Michael A had unloaded 49,100 shares at $102.25 per share in a transaction on June 8, 2016. The total value of transaction was $5,020,475. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Edwards Lifesciences Corporation (NYSE:EW) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.39 points or 0.38% at $101.13 with 865,296 shares getting traded. Post opening the session at $101.22, the shares hit an intraday low of $100.91 and an intraday high of $102.55 and the price was in this range throughout the day. The company has a market cap of $21,416 million and the number of outstanding shares have been calculated to be 211,762,740 shares. The 52-week high of Edwards Lifesciences Corporation (NYSE:EW) is $112 and the 52-week low is $62.53.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.